CD40LG and in situ carcinoma: Markers of B cell differentiation and/or activation were therefore compared in CIS/MS patients with and without serum IgM antibodies (Ab) to EBV viral capsid (VCA) antigen, used as a marker of recent EBV re-activation (VCA IgM Ab+).